ENTA—Have [the SAPHIRE-1 and SAPHIRE-2 results had] no implication for your market share of 38%?
I’m waiting for the results from ABBV/ENTA’s PEARL-3 and PEARL-4 and from GILD’s ION-2 and ION-3 before considering a change to the model’s 38% market share for ABBV/ENTA’s regimen. Top-line data from all four of these trials are expected soon (#msg-94927196, #msg-94014357).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”